公开(公告)号：WO2013130669A8

公开(公告)日：2014-03-27

申请号：PCT/US2013028097

申请日：2013-02-27

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  JAMZAD SHAHLA ,  CAESAR JOHN P JR ,  FAWAZ MAJED ,  DAS LAURA ,  GU CHONG-HUI ,  HURTER PATRICIA NELL ,  ISRANI MEGHNA JAI ,  JOHNSTON MEGHAN M ,  KNEZIC DRAGUTIN ,  KUZMISSION ANDREW G ,  WANG HONGREN

IPC: A61K31/47 ,  A61K9/16 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K9/205 ,  A61K9/143 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/4808 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/38 ,  C07D215/56

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-Bis( 1,1 -dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

Abstract translation: 本发明涉及含有N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺的固体分散体的药物组合物，其包括 粉末，颗粒和微型片剂的固体分散体，粉末的制造和加工方法，颗粒剂和迷你片剂，以及使用该药物组合物治疗囊性纤维化的方法。

公开(公告)号：WO2011112922A3

公开(公告)日：2012-05-03

申请号：PCT/US2011028081

申请日：2011-03-11

Applicant: VERTEX PHARMA ,  DOKOU ELENI ,  KNEZIC DRAGUTIN

Inventor： DOKOU ELENI ,  KNEZIC DRAGUTIN

IPC: A61K9/16 ,  A61K9/14 ,  A61K9/20

CPC classification number: A61K9/2054 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2077

Abstract: The pharmaceutical composition including a co-crystal. The co-crystal includes a) a co-former; and b) an active pharmaceutical ingredient (API) with solubility in water is less than one part by weight of the API in ten parts by weight of water. Furthermore, the formulation includes a polymer, and a weight ratio of the co-crystal to the polymer is about 0.5:99.5 to about 99.5:0.5. The kinetic solubility of the co-crystal after being in contact with an environment of use is at a therapeutically acceptable level for a prolonged period of time.

Abstract translation: 该药物组合物包括共晶体。 共晶包括a）共同成员; 和b）在水中溶解度的活性药物成分（API）小于10重量份水中API的1重量份。 此外，制剂包括聚合物，共晶与聚合物的重量比为约0.5:99.5至约99.5:0.5。 在与使用环境接触后，共晶体的动力学溶解度长时间处于治疗上可接受的水平。

公开(公告)号：MA55774A

公开(公告)日：2022-03-30

申请号：MA55774

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  PHENIX BRIAN DEAN ,  WAGGENER SARA A

IPC: A61K31/404 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/47 ,  A61K45/06 ,  C07D209/04 ,  C07D215/00

公开(公告)号：HUE055369T2

公开(公告)日：2021-11-29

申请号：HUE18173500

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K45/06 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/47 ,  C07D209/04 ,  C07D215/00

公开(公告)号：LT3424534T

公开(公告)日：2021-11-10

申请号：LT18173500

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K45/06 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  C07D209/04 ,  C07D215/00

公开(公告)号：CA2865519C

公开(公告)日：2018-01-02

申请号：CA2865519

申请日：2013-02-27

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  JAMZAD SHAHLA ,  CAESAR JOHN P JR ,  FAWAZ MAJED ,  DAS LAURA ,  GU CHONG-HUI ,  HURTER PATRICIA NELL ,  ISRANI MEGHNA JAI ,  JOHNSTON MEGHAN M ,  KNEZIC DRAGUTIN ,  KUZMISSION ANDREW G ,  WANG HONGREN

IPC: A61K31/47 ,  A61K9/16 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

公开(公告)号：AU2015247850A1

公开(公告)日：2016-10-06

申请号：AU2015247850

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: C07D209/04 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  A61K45/06 ,  C07D215/00

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

公开(公告)号：AU2013226076A1

公开(公告)日：2014-09-18

申请号：AU2013226076

申请日：2013-02-27

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  JAMZAD SHAHLA ,  CAESAR JR JOHN P ,  FAWAZ MAJED ,  DAS LAURA ,  GU CHONG-HUI ,  HURTER PATRICIA NELL ,  ISRANI MEGHNA JAI ,  JOHNSTON MEGHAN M ,  KNEZIC DRAGUTIN ,  KUZMISSION ANDREW G ,  WANG HONGREN

IPC: A61K31/47 ,  A61K9/16 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

公开(公告)号：CA2865519A1

公开(公告)日：2013-09-06

申请号：CA2865519

申请日：2013-02-27

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  JAMZAD SHAHLA ,  CAESAR JOHN P JR ,  FAWAZ MAJED ,  DAS LAURA ,  GU CHONG-HUI ,  HURTER PATRICIA NELL ,  ISRANI MEGHNA JAI ,  JOHNSTON MEGHAN M ,  KNEZIC DRAGUTIN ,  KUZMISSION ANDREW G ,  WANG HONGREN

IPC: A61K31/47 ,  A61K9/16 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

公开(公告)号：AU2011293135A8

公开(公告)日：2013-05-02

申请号：AU2011293135

申请日：2011-08-26

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  JAMZAD SHAHLA ,  DAS LAURA ,  ISRANI MEGHNA JAI ,  KNEZIC DRAGUTIN ,  KUZMISSION ANDREW G

IPC: A61K9/14 ,  A61K9/16 ,  A61K31/47

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-B is( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3- carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition.